Avieum Life Sciences aims to develop novel inhibitors of Pseudomonas aeruginosa using Fragment based drug discovery approach and by using siderophores as drug delivery agents.
The company also supports global pharmaceutical R&D organizations to accelerate their drug discovery research.
With a proven expertise in synthetic and medicinal chemistry, pre-clinical drug discovery and fragment based drug discovery, the company offer services to support drug discovery from hit identification to lead optimization, custom synthesis, impurity synthesis, reference standards, route scouting and process development.
The company is founded by Dr. Ramesh Kale who did his PhD in Synthetic Organic Chemistry from CSIR-NCL and has 12 years of experience in synthetic and medicinal chemistry, drug discovery and pathogen detection.
Website: http://www.avieum.com/